OBJECTIVE: We observed 3 @entity1 who developed severe venous and arterial @entity1031 events during treatment with adalimumab, 2 of whom had @entity309 ( @entity309 ) and 1 of whom had @entity5144 . Antiadalimumab antibodies were detected in all 3 @entity1 . We undertook this study to determine whether the development of antiadalimumab antibodies was associated with @entity1031 events during adalimumab treatment. METHODS: A retrospective search (with blinding with regard to antiadalimumab antibody status) for @entity1031 events was performed in a prospective cohort of 272 consecutively included adalimumab-treated @entity309 @entity1 . Incidence rates were calculated and hazard ratios (HRs) were estimated using Cox regression. None of the index @entity1 were part of the cohort. RESULTS: Antiadalimumab antibodies were detected in 76 of 272 @entity1 (28%). Eight @entity1031 events were found, 4 of which had occurred in patients with antiadalimumab antibodies. The incidence rate was 26.9/1,000 @entity1 -years for patients with antiadalimumab antibodies and 8.4/1,000 @entity1 -years for @entity1 without those antibodies (HR 3.8 [95% confidence interval 0.9-15.3], P = 0.064). After adjustment for duration of followup, age, body mass index, erythrocyte sedimentation rate, and prior @entity1031 events, the HR was 7.6 (95% confidence interval 1.3-45.1) (P = 0.025). CONCLUSION: These findings suggest that the occurrence of venous and arterial @entity1031 events during adalimumab treatment is higher in patients with antiadalimumab antibodies than in those without antiadalimumab antibodies. Patient numbers were relatively small; therefore, validation in other cohorts is mandatory.

Venous and arterial XXXX events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study.

@entity1 :: ('9606', 'Species') :: ['patients', 'person'] @entity1031 :: ('MESH:D013923', 'Disease') :: ['thromboembolic'] @entity309 :: ('MESH:D001172', 'Disease') :: ['rheumatoid arthritis', 'RA'] @entity5144 :: ('MESH:D015535', 'Disease') :: ['psoriatic arthritis']
@entity1031 :: (MESH:D013923,Disease) :: ['thromboembolic']
